Skip to content
Business

Novo Nordisk Shares Slump as Investors Shrug Off 2030 Blockbuster Targets

Novo Nordisk targeted more than five blockbusters by 2030 and over DKK 150 billion of pipeline sales in 2035, but its shares fell as much as 9 percent as investors questioned the goals.

Blue Novo Nordisk flags fly at the entrance to the company's production site in Kalundborg, Denmark.
Photo: Johan Wessman, News Øresund / Wikimedia Commons, CC BY 2.0

Novo Nordisk shares fell sharply on Monday after the Wegovy maker set out its long-term targets at a capital markets day in London. Investors questioned whether the goals were enough to turn round a stock that has already lost more than 70 percent of its value since its peak.

The Danish drugmaker's shares dropped as much as 9 percent in Copenhagen before paring some of the fall; at 11:24 GMT they were 4.7 percent lower. The selling took the stock to its lowest level since April, according to Philip Jagd, head of equities at the pension fund Sampension.

The slide matters well beyond Denmark. The launch of Wegovy in 2021 pushed Novo's market value above $600 billion, making it one of Europe's best-known growth stories. Much of that valuation has since been eroded by competition, pricing pressure and weaker sales forecasts.

The targets Novo put to investors

Chief executive Mike Doustdar told investors the company aims to launch more than five blockbuster medicines by 2030, meaning products with net sales above $1 billion a year. It also targets more than 150 billion Danish crowns, about $23 billion, of sales in 2035 from products that have not yet launched.

That 2035 figure is built on internal, risk-adjusted pipeline assets and leaves out any future acquisitions. Novo also wants to widen its reach beyond obesity and diabetes, with medicines for liver and cardiovascular disease among the areas it named.

Novo's capital markets day in numbers

  • 9% biggest intraday fall in the shares on Monday
  • DKK 150bn+ pipeline sales targeted for 2035
  • 60 million+ patients targeted by 2030

The company aims to reach more than 60 million patients worldwide by 2030. It plans to scale up manufacturing tenfold so it can supply 15 million patients with oral obesity treatments by the end of the decade, and wants at least five oral drug candidates in clinical trials by the end of this year.

Novo Nordisk: share price, chart and news

The curved white NN1 headquarters building of Novo Nordisk in Bagsværd, seen from the street behind trees.
The curved white NN1 headquarters building of Novo Nordisk in Bagsværd, seen from the street behind trees. Photo: Toxophilus / Wikimedia Commons, CC BY-SA 4.0

Why the market was unimpressed

Analysts focused on what the targets did not promise. The 2030 sales goal assumes only stable margins, which Markus Manns, a portfolio manager at Union Investment, described as "slightly underwhelming". He added that it was not a big surprise and that the guidance looked reasonable given biosimilar competition in Canada, Brazil and China and rival products from Amgen and Pfizer from 2028.

Pricing was the sharper concern. Semaglutide, the active ingredient in both Wegovy and Ozempic, loses patent protection in the early 2030s, and analysts questioned whether Novo's next-generation drugs can hold premium prices once cheaper versions of its current blockbuster are on the market.

Analysts and investors who spoke to the Danish business daily Børsen said the presentation lacked concrete goals and voiced concern about growth in the weight-loss market. In a written comment to the news agency Ritzau, Jagd said Novo's sales projections had worsened substantially over the past few years and that the company needed to show it can grow with the sector.

Lilly's lead in obesity drugs

The backdrop is a market Novo once dominated. Eli Lilly's Zepbound is on track to outsell Wegovy by more than $7 billion this year, according to LSEG data, a measure of how far the American rival has moved ahead.

The tablet is one bright spot. Doustdar said the oral version of Wegovy has reached a record 7 million US prescriptions to date, with about 90 percent of those sales going through direct cash-pay channels rather than insurers. That route gives Novo more direct contact with patients, but it also leaves sales more exposed to price-sensitive consumers.

The injectable pipeline is the next test:

MedicinePlanned timing
CagriSema (combination)Launch targeted for early next year
Cagrilintide alone and high-dose CagriSema2028
ZenagamtideAfter those launches; oral and injectable forms together

Chief scientific officer Martin Holst Lange said the oral and injectable versions of zenagamtide would be launched at the same time rather than the injection first.

Room for bigger deals and a smaller workforce

Executives told investors the balance sheet can support larger acquisitions, not only small bolt-on deals. That opens the door to a bigger purchase to fill the gap left as semaglutide approaches the end of its exclusivity.

Novo has also been shrinking. Under a cost-cutting drive that began last year, staff departures have reached 13,000, the company disclosed on Monday, made up of an initial 9,000 job cuts and about 4,000 further exits since.

For shareholders, the message from Monday's trading is that targets alone will not restore confidence. The market wants evidence that Novo can grow with the obesity sector rather than lose share in it, and the next set of quarterly results will be read with that question in mind.

Sources

Related stories

Investing

Novo Nordisk Raises Its 2026 Outlook as the Wegovy Pill Takes Off

Novo Nordisk's adjusted operating profit rose 27% to DKK 31.7bn in the third quarter, helped by DKK 5.4bn of Wegovy pill sales, and it now sees 2026 growth of minus 2% to plus 2%.

Business

Novo Nordisk Says Early CagriSema Responders Lost 25.4% of Body Weight in 68 Weeks

Novo Nordisk says patients who responded early to its obesity shot CagriSema lost 25.4% of their body weight in 68 weeks, but the post hoc analysis is no guide to treatment yet.

Markets

Meta Soars 12.9% and AMD Hits $1 Trillion as the AI Rally Lifts the Nasdaq 3.3%

Meta rose 12.9% on the week after its Muse assistant topped Apple's app chart, and AMD passed a $1tn market value. The Nasdaq 100 gained 3.25%, while Novo Nordisk fell 10.14% and…

Markets

Novartis Sinks 13.5% on Twin Trial Failures as Brent Breaks $100 and the ECB Hikes

Novartis fell 13.54% in the week to 11 September after two late-stage trial failures, while Brent jumped 8.65% to $104.61 a barrel and the ECB raised rates for the second time this…

Business

Québecor Makes a C$31bn Cash-and-Share Bid for Telus, Which Warns of Regulatory Risk

Québecor has offered C$6.35 in cash plus 0.17 of its own shares for each Telus share, a bid worth about C$31bn. The Telus board says the price falls short and the regulatory risk…

Business

Tyson Foods Shares Jump 8.7% as Beef Outlook Outweighs a $74m Quarterly Loss

Tyson Foods posted a $74m fourth-quarter net loss and adjusted EPS of $0.61, down 47%, yet its shares closed 8.7% higher on Monday as its 2027 beef outlook pointed to far smaller…

Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is…

Business

ULA Loses Its First Mission as Vulcan Rocket Fails With 40 Amazon Leo Satellites on Board

United Launch Alliance's Vulcan rocket failed about 10 minutes after lift-off on Sunday, and all 40 Amazon Leo satellites were lost. Amazon fell 3.3% on Monday as space stocks…